Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma October 2, 2024
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma October 2, 2024
Mavenir’s Energy-Efficient 5G UPF Solution Wins Leading Lights Network Energy Efficiency Award October 2, 2024
Mavenir’s Energy-Efficient 5G UPF Solution Wins Leading Lights Network Energy Efficiency Award October 2, 2024
Foreign Minister and Vatican Ambassador Discuss Strategies to Enhance Global Peace and Coexistence April 30, 2026
